| DC Field | Value | Language |
| dc.contributor.author | Scutari, Adrian | - |
| dc.contributor.author | Leşan, Octavian | - |
| dc.contributor.author | Cazacu, Oleg | - |
| dc.contributor.author | Borcoman, Marian | - |
| dc.date.accessioned | 2026-10-30T12:50:28Z | - |
| dc.date.accessioned | 2026-11-17T12:33:09Z | - |
| dc.date.available | 2026-10-30T12:50:28Z | - |
| dc.date.available | 2026-11-17T12:33:09Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | Scutari, Adrian; Leşan, Octavian; Cazacu, Oleg; Borcoman, Marian. NEW PERSPECTIVES IN PROSTATE BIOPSY: THE CONTRIBUTION OF ARTIFICIAL INTELLIGENCE. In: MedEspera 2026, p. 504. ISBN 978-9975-82-486-6. | en_US |
| dc.identifier.isbn | 978-9975-82-486-6 | - |
| dc.identifier.uri | https://medespera.md/documents/abstract-book-4.pdf | - |
| dc.identifier.uri | https://repository.usmf.md/handle/20.500.12710/34320 | - |
| dc.description | Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova | en_US |
| dc.description.abstract | Introduction. Nowadays, artificial intelligence (AI) is increasingly integrated not only into clinical practice, but also to a great extent in imaging-based specialties and histopathological interpretation. For instance, biopsy remains the cornerstone of prostate cancer (PCa) diagnostics. Even so, both systematic transrectal ultrasound guided biopsy and mpMRI-targeted biopsy are associated with clinically relevant false-negative rates and interobserver variability. False-negative rates range between 10% and 34%, with standard 12-core systematic biopsy potentially missing up to 30-40% of PCa in specific contexts. Also, a proportion of patients with an initially negative biopsy are subsequently diagnosed with PCa under repeated samples, drawing attention to the fundamental limitations embedded in current diagnostic procedures. Within this context, AI has emerged as a potential tool to strengthen diagnostic performance in lesion detection and improve procedural accuracy. Aim of study. The aim of this review is to assess current scientific evidence that refers to the contribution of AI in order to improve the diagnostic performance of prostate biopsy. Methods and materials. A comprehensive narrative survey of recent literature (2019-2025) was conducted using PubMed, Web of Science, and Google Scholar databases. Results. Large international validation data (PI-CAI study) demonstrated that an MRI-based AI system achieved an area under the receiver operating characteristic curve (AUROC) of 0.91 compared with 0.86 for radiologists, detecting 6.8% more Grade Group >2 cancers at matched specificit y. AI reduced false-positive findings by approximately 50% and decreased detection of indolent tumors by about 20% when sensitivity was matched. A meta-analysis including over 7,000 patients reported higher pooled sensitivity (86.5% vs 82.6%) and specificity (57.8% vs 50.0%) for AI-assisted MRI interpretation compared with unassisted readings in detecting clinically significant PCa. At lesion level, AI improved sensitivity from approximately 40% to 59%, and increased patient-level specificity from about 58% to 72%, while maintaining overall sensitivity near 94%. In digital pathology, AI-based systems have demonstrated high accuracy in automated cancer detection and Gleason grading, reducing interobserver variability. Conclusions. Current scientific evidence supports incorporating AI across multiple stages of the prostate biopsy pathway. AI has demonstrated potential to improve the accuracy of lesion detection, enhance targeting precision, establish standardized criteria for histopathological interpretation, and ultimately optimize detection of clinically significant disease. AI-assisted biopsy marks a meaningful advancement toward more precise, safer, and more efficient PCa diagnostics. | en_US |
| dc.publisher | Centrul Editorial-Poligrafic Medicina | en_US |
| dc.relation.ispartof | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 | en_US |
| dc.subject | Artificial Intelligence | en_US |
| dc.subject | Prostate Biopsy | en_US |
| dc.subject | mpMRI-TRUS Fusion | en_US |
| dc.subject | Transperineal | en_US |
| dc.subject | Digital Pathology | en_US |
| dc.title | NEW PERSPECTIVES IN PROSTATE BIOPSY: THE CONTRIBUTION OF ARTIFICIAL INTELLIGENCE | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | MedEspera 2026
|